drugset / Trial / NCT00445003

Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy

NCT00445003

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to find out if treatment with an intravitreal injection of triamcinolone or an intravitreal injection of ranibizumab can prevent loss of vision caused by panretinal photocoagulation treatment. At the present time, it is not known whether intravitreal steroid or anti-vascular endothelial growth factor (anti-VEGF) injections are beneficial in preventing vision loss after panretinal photocoagulation (PRP) treatment. It is possible that one or both of the types of injections will prevent vision loss after PRP treatment. However, it is not known whether the benefits of the injections will outweigh the risks. It is possible that because of side effects, the injections may not be as good as laser alone in treating the diabetic retinopathy.

Timeline

Start
2007-03
Primary completion
2009-10
Completion
2010-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody 0.5 mg Intravitreal
Comparator Triamcinolone Acetonide Other / unclassified 4 mg Intravitreal